2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thrombocytopenias, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

3023 Heterogeneity in efficacy outcomes in immune thrombocytopenia clinical trials: A systematic review

Adam Cuker, MD, MS, Ver Bilano, MSc, PhD2, Jincy Paulose, MD3, Mary Lisha Paul, MD4, Emer O Sullivan, MSc5, Dave Nellesen, PhD6, Samantha Kaufhold, MPH7, Olivia Shane, MPH8, Neema Lema, MPH9, Olivia Reese, MPH10, Adrienne Kwok, MPH11, Soyon Lee, PharmD, MPH12
1 Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Novartis Pharmaceuticals Uk, London, United Kingdom
3 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
4 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
5 Novartis Ireland Limited, Dublin, Ireland
6 Analysis Group, San Francisco, California, United States
7 Analysis Group, Menlo Park, California, United States
8 Analysis Group, San Francisco, California, United States
9 Analysis Group, Menlo Park, California, United States
10 Analysis Group, Menlo Park, California, United States
11 Analysis Group, San Francisco, California, United States
12 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States

Background: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts and an increased risk of bleeding. Although multiple therapeutic options are available and new therapies continue to emerge, treatment selection is often informed by inconsistently reported clinical trial outcomes. Current guidelines emphasize achieving platelet counts to prevent bleeding, rather than normalization. A systematic evaluation of clinical outcome measures is needed to contextualize existing evidence and inform harmonized approaches in ITP research.

Objective: To identify and characterize efficacy outcome measures assessed in clinical trials of ITP.

Methods: A systematic search of the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase, and MEDLINE via Ovid was conducted on November 12, 2025, in accordance with Preferred Reporting Items for systematic reviews and Meta-Analyses (PRISMA) reporting guidelines. This review protocol was registered prospectively in PROSPERO (CRD420251271703). Two independent reviewers screened publications for relevance at 2 levels using predefined criteria, with disagreements adjudicated by a third reviewer. English-language publications from January 2015 onward were eligible if they evaluated adults with primary ITP in phase 3 clinical trials and reported efficacy outcomes. Interventions were required to either be FDA-approved for ITP or included by name or class in the forthcoming 2026 ASH ITP guidelines. Combination therapies were eligible if each individual agent qualified. No geographic restrictions were applied. Outcomes were summarized at the trial level and reported for complete intervention groups at the latest timepoint available.

Results: Overall, 1207 unique publications were screened; 44 publications representing 33 unique phase 3 trials met eligibility criteria. Trials evaluated 13 unique treatments as monotherapy or in combination, representing 8 treatment classes.

Platelet response was the most frequently reported response outcome, reported in 30 trials and commonly defined as platelet count ≥50×109/L (29 trials) and/or ≥30×109/L (18 trials). Definitions were heterogeneous, often including additional criteria such as the absence of bleeding or rescue therapy, or a ≥2-fold increase in platelet count from baseline. Across trials and intervention arms, treatment period assessment windows ranged from day 5 to week 26, and platelet response rates ranged from 30.8% to 94.7% for platelet count ≥50×109/L and from 26.9% to 100.0% for platelet count ≥30×109/L.

Complete response (CR) was reported in 16 trials and consistently defined as platelet count ≥100×109/L (15 trials). However, assessment timing and additional qualifying criteria varied. CR rates across intervention arms ranged from 17.2% to 84.4%. The lowest value required this response to be measured on ≥2 occasions ≥7 days apart, whereas the highest value only required 1 such measurement.

Durable response (DR) was explicitly defined and reported in 7 trials. DR definitions varied by platelet threshold, minimum response duration, rescue therapy requirements, and assessment window. DR rates across intervention arms ranged from 22.0% to 88.0% (achieved among pre-treated patients who previously achieved DR with TPO-RAs), with assessment windows varying from 6 to 26 weeks.

Other measures of response included sustained, stable, and partial response and were less frequently reported, with outcome values appearing in 3, 6, and 4 trials, respectively. Bleeding events were reported in 31 trials and ranged from 0.0% to 80.6%, while rescue therapy was reported in 20 trials and ranged from 1.4% to 47.0%. The proportion of patients with treatment failure was reported in 5 trials, with inconsistent definitions across studies; only 2 trials reported the time to treatment failure.

Conclusion: Phase 3 clinical trials in primary ITP demonstrate substantial heterogeneity in clinical outcome definitions and reporting, particularly for platelet response and DR. Differences in response definitions, timing, patient populations, and treatments limit cross-trial comparisons and complicate interpretation of treatment benefit. Standardized response definitions and prespecified assessment approaches may improve interpretation of treatment efficacy across ITP trials, enabling more meaningful comparisons and helping differentiate therapies capable of achieving durable, clinically meaningful benefit.

Adam Cuker, MD, MS: Equilibra - Research Funding; Novartis - Research Funding; Sanofi - Research Funding; Equilibra - Research Funding; Pfizer - Research Funding; Novartis - Research Funding; Takeda - Research Funding; Takeda - Research Funding; Novo Nordisk - Research Funding; Pfizer - Research Funding; Sanofi - Research Funding; UpToDate - Patents & Royalties; UpToDate - Patents & Royalties; Incyte - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)